Literature DB >> 23446735

Novel diagnostic assays for heparin-induced thrombocytopenia.

Adam Cuker1, Ann H Rux, Jillian L Hinds, May Dela Cruz, Serge V Yarovoi, Isola A M Brown, Wei Yang, Barbara A Konkle, Gowthami M Arepally, Stephen P Watson, Douglas B Cines, Bruce S Sachais.   

Abstract

Laboratory testing for heparin-induced thrombocytopenia (HIT) has important shortcomings. Immunoassays fail to discriminate platelet-activating from nonpathogenic antibodies. Specific functional assays are impracticable due to the need for platelets and radioisotope. We describe 2 assays that may overcome these limitations. The KKO-inhibition test (KKO-I) measures the effect of plasma on binding of the HIT-like monoclonal antibody KKO to platelet factor 4 (PF4)/heparin. DT40-luciferase (DT40-luc) is a functional test comprised of a B-cell line expressing FcγRIIa coupled to a luciferase reporter. We compared these assays to polyspecific and immunoglobulin (Ig)G-specific PF4/heparin enzyme-linked immunosorbent assays (ELISAs) in samples from 58 patients with suspected HIT and circulating anti-PF4/heparin antibodies. HIT was defined as a 4Ts score ≥ 4 and positive (14)C-serotonin release assay. HIT-positive plasma demonstrated greater mean inhibition of KKO binding than HIT-negative plasma (78.9% vs 26.0%; P < .0001) and induced greater luciferase activity (3.14-fold basal vs 0.96-fold basal; P < .0001). The area under the receiver-operating characteristic curve was greater for KKO-I (0.93) than for the polyspecific (0.82; P = .020) and IgG-specific ELISA (0.76; P = .0044) and for DT40-luc (0.89) than for the IgG-specific ELISA (P = .046). KKO-I and DT40-luc showed better discrimination than 2 commercially available immunoassays, are simple to perform, and hold promise for improving the specificity and feasibility of HIT laboratory testing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446735      PMCID: PMC3643769          DOI: 10.1182/blood-2013-01-479576

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.

Authors:  Miri Blank; Yehuda Shoenfeld; Sigal Tavor; Sonja Praprotnik; Marie Claire Boffa; Babette Weksler; M Jeanine Walenga; Jean Amiral; Amiram Eldor
Journal:  Int Immunol       Date:  2002-02       Impact factor: 4.823

3.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

5.  Heparin-associated thrombocytopenia.

Authors:  D B Cines; P Kaywin; M Bina; A Tomaski; A D Schreiber
Journal:  N Engl J Med       Date:  1980-10-02       Impact factor: 91.245

Review 6.  Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Adam Cuker; Phyllis A Gimotty; Mark A Crowther; Theodore E Warkentin
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

7.  Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.

Authors:  M P Reilly; S M Taylor; N K Hartman; G M Arepally; B S Sachais; D B Cines; M Poncz; S E McKenzie
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

8.  A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.

Authors:  A Greinacher; I Michels; V Kiefel; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

9.  A diagnostic test for heparin-induced thrombocytopenia.

Authors:  D Sheridan; C Carter; J G Kelton
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

10.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more
  13 in total

Review 1.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

2.  Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

Review 3.  Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  H D Husseinzadeh; P A Gimotty; A M Pishko; M Buckley; T E Warkentin; A Cuker
Journal:  J Thromb Haemost       Date:  2017-05-11       Impact factor: 5.824

4.  Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Authors:  Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 5.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 6.  Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Authors:  Zheng Cai; Zhiqiang Zhu; Mark I Greene; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

7.  DiagnoSTic assays for heparin-induced thrombocytopenia.

Authors:  Elizabeth E Gardiner; Robert K Andrews; Adam Cuker
Journal:  Br J Haematol       Date:  2014-05-14       Impact factor: 6.998

8.  Atomic description of the immune complex involved in heparin-induced thrombocytopenia.

Authors:  Zheng Cai; Serge V Yarovoi; Zhiqiang Zhu; Lubica Rauova; Vincent Hayes; Tatiana Lebedeva; Qun Liu; Mortimer Poncz; Gowthami Arepally; Douglas B Cines; Mark I Greene
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

Review 9.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

10.  Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia.

Authors:  B D Wines; C W Tan; E Duncan; S McRae; R I Baker; R K Andrews; S Esparon; E E Gardiner; P M Hogarth
Journal:  J Thromb Haemost       Date:  2018-11-20       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.